Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 233.45M -3.3% |
| Revenue (ttm) | n/a |
| Net Income | -98.56M |
| EPS | -0.99 |
| Shares Out | 81.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,038,692 |
| Open | 2.640 |
| Previous Close | 2.605 |
| Day's Range | 2.610 - 2.915 |
| 52-Week Range | 1.350 - 4.490 |
| Beta | 0.96 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+213.59%) |
| Est. Earnings | Nov 24, 2026 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 213.59% from the latest price.
News
Eledon Pharmaceuticals presents patient-reported outcomes data from BESTOW trial
Eledon Pharmaceuticals (ELDN) announced new patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational immunosuppression therapy. The data showed s...
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occ...
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephr...
Eledon Pharmaceuticals updates long-term data from Phase 2 BESTOW trial
Eledon Pharmaceuticals (ELDN) announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented at the Internati...
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolim...
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegopru...
Eledon files islet cell transplant application, plans Phase 3 kidney trial
Eledon Pharmaceuticals (ELDN) announced significant progress across multiple tegoprubart development programs in kidney allotransplantation and islet cell transplantation. Eledon has submitted an Inve...
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated stu...
Eledon Pharmaceuticals reports Q2 EPS (27c), consensus (15c)
“During the first half of the year, we made meaningful progress establishing the regulatory framework for our planned Phase 3 kidney transplantation program, which we expect to initiate later this…
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data prese...
Eledon Pharmaceuticals Earnings release: Q2 2026
Eledon Pharmaceuticals released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Eledon Pharmaceuticals Quarterly report: Q2 2026
Eledon Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 13, 2026.
Eledon Pharmaceuticals Slides: Corporate presentation
Eledon Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Eledon Pharmaceuticals initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Seema Sheoran initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target implying 200% upside from current levels. The company is developing…
Natera, Eledon announce strategic partnership
Natera (NTRA) and Eledon Pharmaceuticals (ELDN) announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of teg...
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage...
Eledon Pharmaceuticals Transcript: Study result
Long-term data show tegoprubart provides superior kidney function, fewer rejections after six months, and a better safety and quality of life profile compared to tacrolimus in kidney transplant patients. In islet cell transplantation, all patients achieved insulin independence and no severe hypoglycemic events, with high patient interest and favorable safety.
Eledon Pharmaceuticals Press release: Study result
Eledon Pharmaceuticals issued a press release on June 22, 2026, disclosing material business information to investors.
Eledon Pharmaceuticals Slides: Study result
Eledon Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
Eledon Pharmaceuticals announces new long-term data from BESTOW program
Eledon Pharmaceuticals (ELDN) announced new long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented in oral and poster p...
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
Eledon Pharmaceuticals announces updated results from tegoprubart trial
Eledon Pharmaceuticals (ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free im...
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an Hb...
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at ADA
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in ...